Who
Jon P. Stonehouse
Director
Company insider
Files Form 4 as: Chief Executive Officer, BioCryst Pharmaceuticals; Director, Metsera; Director, Bellicum Pharmaceuticals.
In numbers
- Trades disclosed
- 187
- Buys
- 15
- Sells
- 9
- Bought
- $630K
- Sold
- $10.0M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 5 Jan 2007
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $6,247644 at $9.70 | filing |
| 31 Aug 2026filed 2 Sep 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $6,247644 at $9.70 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,622631 at $8.91 | filing |
| 29 May 2026filed 2 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $5,622631 at $8.91 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $985K305,995 at $3.22 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $2.6M305,995 at $8.64 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —305,995 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —305,995 at $0.00 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $985K305,995 at $3.22 | filing |
| 2 Mar 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $2.6M305,995 at $8.64 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $3,684421 at $8.75 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $3,684421 at $8.75 | filing |
| 19 Dec 2025filed 23 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $458K61,793 at $7.41 | filing |
| 18 Dec 2025filed 19 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —20,000 at $0.00 | filing |
| 18 Dec 2025filed 19 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
| 18 Dec 2025filed 19 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —10,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.